Therapeutic targets in the treatment of allograft fibrosis.
about
Fibrogenesis: Mechanisms, Dynamics and Clinical ImplicationsCellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus.Correlation between PKB/Akt, GSK-3β expression and tubular epithelial-mesenchymal transition in renal allografts with chronic active antibody-mediated rejection.Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection.Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation.Late kidney allograft loss: what we know about it, and what we can do about itEvaluation of gene panel mRNAs in urine samples of kidney transplant recipients as a non-invasive tool of graft functionEarly epithelial phenotypic changes predict graft fibrosis.Novel Therapeutics Identification for Fibrosis in Renal Allograft Using Integrative Informatics Approach.Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis.TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection.Contribution of epithelial plasticity to renal transplantation-associated fibrosis.Assessment of kidney organ quality and prediction of outcome at time of transplantation.Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following TransplantationBiological pathways and potential targets for prevention and therapy of chronic allograft nephropathyModulation of Wnt and Hedgehog signaling pathways is linked to retinoic acid-induced amelioration of chronic allograft dysfunction.Effect of earlier-proteinuria on graft functions after one-year living donor renal transplantation.Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection.TGFbeta neutralization within cardiac allografts by decorin gene transfer attenuates chronic rejection.Upregulation of transglutaminase and ε (γ-glutamyl)-lysine in the Fisher-Lewis rat model of chronic allograft nephropathy.Glomerular damage as a predictor of renal allograft loss.Long-term outcomes following sirolimus conversion after renal transplantation.Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma.Reduction of chronic allograft nephropathy by inhibition of extracellular signal-regulated kinase 1 and 2 signaling.Diffuse myocardial fibrosis among healthy pediatric heart transplant recipients: Correlation of histology, cardiovascular magnetic resonance, and clinical phenotype.Adeno-associated viral vector-mediated interleukin-10 prolongs allograft survival in a rat kidney transplantation model.Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants.Cyclosporine-mediated allograft fibrosis is associated with micro-RNA-21 through AKT signaling.Reduction of chronic rejection of renal allografts by anti-transforming growth factor-β antibody therapy in a rat model
P2860
Q26782466-BED1F833-F509-4114-90D2-DB923BEE2C42Q30301338-03107142-3AF2-4BFE-9B7C-2CB1F12D7622Q33724166-5B209BE7-437B-471E-878C-93483C604667Q33811918-E205D31B-4DD4-4378-ACA9-AA94DDD8BD13Q34289498-890C607B-FAC2-44DE-BF6D-954CF13E020DQ35153318-0B2CDC7A-F613-4207-9A2C-CE1CE49A838BQ35868684-D8A10737-FA5F-41A9-A2C3-598FF6CC2690Q36796755-B2F4CB8D-E8BF-4C17-A6C2-0F10B75E3995Q37554477-DD28EF43-BAC7-4679-A83A-E7D4098623C8Q37709678-1BB5474E-70F8-4E01-A588-2A9796A8F2EBQ37773292-E9D31B16-A4B4-43B4-BC0B-A31CF1015906Q37811517-9E3D42E3-FC49-4124-8CD1-ABE3A3B2566EQ37832966-F8426031-5355-48CF-AA50-6400F78A8202Q38008362-AB2CE15F-CB30-4C39-9CEE-FD24958A3C57Q38223778-E77C0607-569E-4F48-87A4-40B7A3B854F3Q39698361-FB4851B5-A93A-4A85-AAF1-1E17650D793DQ41709031-60D9AADD-269D-4394-AB21-A6030A0224F4Q42138480-8FA553E4-CC4C-4848-B7D5-260848BE76D5Q42639607-1C7F271C-3C31-4F4A-BC33-7CA3E8A4E235Q42705890-8B6263CF-ABD8-42AC-AA15-0C795DDD8D85Q43065199-A132097F-6784-42E3-9BC7-5EBC457DDB9AQ44544352-F10D1C49-5432-4C3E-A826-4E72E2A0030FQ44911053-ABB4ED90-58C1-48EC-9063-9B836DDD537CQ46492805-075C02F7-1A6C-4AE5-B597-27CEDAB5E320Q48337289-C62C5292-B728-41E1-998E-A0D31529E8A4Q50687724-4FD712FB-4804-4EB3-87EE-F36E72454128Q51904875-FD2EF256-64AC-42ED-A9AE-E0861DD5B16CQ53015584-B79B435C-0F71-4EF6-BEAD-80ED3CD5F293Q56704568-C5AB0339-62AC-4233-9C1D-68E2ED5FEFAB
P2860
Therapeutic targets in the treatment of allograft fibrosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Therapeutic targets in the treatment of allograft fibrosis.
@ast
Therapeutic targets in the treatment of allograft fibrosis.
@en
type
label
Therapeutic targets in the treatment of allograft fibrosis.
@ast
Therapeutic targets in the treatment of allograft fibrosis.
@en
prefLabel
Therapeutic targets in the treatment of allograft fibrosis.
@ast
Therapeutic targets in the treatment of allograft fibrosis.
@en
P2860
P1476
Therapeutic targets in the treatment of allograft fibrosis.
@en
P2093
R B Mannon
P2860
P304
P356
10.1111/J.1600-6143.2006.01261.X
P407
P433
P577
2006-05-01T00:00:00Z